



Amylin Pharmaceuticals Announces Departure Of Donald H. Rumsfeld From Board of Directors

SAN DIEGO, Feb. 2 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced the resignation of Donald H. Rumsfeld from its Board of Directors. Mr. Rumsfeld resigned in light of his recent confirmation as US Secretary of Defense. Mr. Rumsfeld served on Amylin's Board from 1991 to 1996, and rejoined the Board in 1999.

"Don Rumsfeld has played a key role in the history of our company. His stalwart support of Amylin, especially during our most challenging times, has been a constant source of strength for the senior management team," said Joseph C. Cook, Jr., Chairman and CEO of Amylin Pharmaceuticals. "We will miss Don, his wise counsel and thoughtful insight."

Amylin Pharmaceuticals is engaged in the discovery, development and commercialization of drug candidates for the treatment of metabolic disorders. The Company's lead drug candidate, SYMLIN™ (pramlintide acetate), is currently under review by the FDA as a potential treatment for people with diabetes who use insulin. The New Drug Application for SYMLIN was submitted in December 2000 and was accepted for filing by the FDA in January 2001. The SYMLIN regulatory submission process for Europe is underway, with a filing expected in the second quarter of 2001. Amylin Pharmaceuticals' second diabetes drug candidate, AC2993, is in Phase 2 evaluation for the treatment of type 2 diabetes, and a long acting release formulation, AC2993 LAR, is in preclinical development. The Company's third drug candidate, AC3056, is currently in Phase 1 evaluation as a potential treatment for metabolic disorders relating to cardiovascular disease. The Company has adopted a commercialization plan for SYMLIN that includes establishment of an internal commercial organization. The Company continues to evaluate arrangements with companies that may add value to its commercialization efforts for SYMLIN in the US as well as in Europe, Japan and other markets. Amylin Pharmaceuticals is based in San Diego, California and has approximately 140 employees. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at www.amylin.com.

This press release contains forward-looking statements about the Company, which involve risks and uncertainties. The Company's actual results could differ materially from those forward-looking statements discussed in this press release, due to risks and uncertainties regarding the drug discovery and development process, uncertainties in FDA review of the Company's NDA for SYMLIN, uncertainties regarding the Company's ongoing clinical studies of its drug candidates and the ability of the Company to commercialize its drug candidates, whether through sales, distribution, marketing and/or corporate partnering agreements, on terms acceptable to the Company or otherwise. Additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, such as its Annual Report on Form 10-K for the fiscal year ended December 31, 1999 under the heading "Risk Factors," and its subsequently filed Quarterly Reports on Form 10-Q. SOURCE Amylin Pharmaceuticals, Inc.

CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., 858-552-2200/